UPDATE: Phase 1 Trial for RAD 402 Dosed the First Patient

Following our previous article, we are pleased to report that patient dosing has commenced in this trial. First patient has been dosed in this Phase 1 dose-escalation trial evaluating RAD 402, an anti-KLK3 (PSA) monoclonal antibody radiolabeled with Terbium-161 (Tb-161), in patients with advanced prostate cancer previously treated with standard therapies. Following our past article, […]

Phase 1 Trial: Dual-Target ADC IDE034 Targets B7-H3/PTK7 in Prostate Cancer

A promising new bispecific antibody-drug conjugate (ADC) known as IDE034 is entering early clinical testing in patients with advanced solid tumors, including prostate cancer, marking a potential step forward in precision oncology. This Phase 1a/1b trial, which began dosing its first patient in February 2026, targets tumors expressing both B7-H3 and PTK7, two surface proteins […]